Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/07/2024 BST			5-day change	1st Jan Change
9.99 ^USD	+7.30%		+32.67%	+53.93%

06-22	Terns Pharmaceuticals, Inc. Presents New Preclinical Data Supporting TERN-501 in Combination with A GLP-1R Agonist for Obesity	CI
05-13	Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Terns Pharmaceuticals to Present at B. Riley Securities' 3rd Annual Oncology Conference

January 13, 2023 at 03:07 pm

Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the B. Riley Securities 3rd Annual Oncology Conference on Wednesday, January 18, 2023 at 2:30 p.m. ET.

A live audio webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns' pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-? agonist, an FXR agonist, a VAP-1 inhibitor, and preclinical small-molecule GLP-1 receptor agonist and GIPR modulator programs.

Contact:

Email: investors@ternspharma.com

Latest news about Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Presents New Preclinical Data Supporting TERN-501 in Combination with A GLP-1R Agonist for Obesity	06-21	CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Terns Pharmaceuticals, Inc. Announces Executive Changes	05-08	CI
Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation	04-29	CI
Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer	04-10	CI
UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating	03-27	MT
North American Morning Briefing : Stocks Struggle After New Records	03-22	DJ
JMP Securities Cuts Terns Pharmaceuticals Price Target to $15 From $17, Maintains Market Outperform Rating	03-18	MT
BMO Capital Adjusts Price Target on Terns Pharmaceuticals to $19 From $18, Maintains Outperform Rating	03-15	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
Terns Pharmaceuticals Gets Orphan Drug Label for Chronic Myeloid Leukemia Treatment Candidate	03-11	MT
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Chief Executive Officer	02-07	CI
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Member of Board of Directors	02-07	CI
Jefferies Adjusts Terns Pharmaceuticals Price Target to $22 From $18, Maintains Buy Rating	01-18	MT
HC Wainwright Adjusts Price Target on Terns Pharmaceuticals to $5.50 From $8, Maintains Neutral Rating	01-10	MT
Mizuho Adjusts Price Target on Terns Pharmaceuticals to $10 From $17, Maintains Buy Rating	11-27	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity	11-02	CI
Terns Pharmaceuticals, Inc.(NasdaqGS:TERN) added to S&P Global BMI Index	18/09/23	CI
HC Wainwright Adjusts Price Target on Terns Pharmaceuticals to $8 From $11, Keeps Neutral Rating	10/08/23	MT
Mizuho Ups Price Target on Terns Pharmaceuticals to $17 From $16, Keeps Buy Rating	09/08/23	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH	08/08/23	CI
Terns Pharmaceuticals Chief Executive Senthil Sundaram Resigns Due to Health Reasons	04/08/23	MT

Chart Terns Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Sector

Biotechnology & Medical Research

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.99 USD

Average target price

14.21 USD

Spread / Average Target

+42.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TERNS PHARMACEUTICALS, INC.	+53.93%	646M
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.94%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research